110 related articles for article (PubMed ID: 30366787)
1. Design, synthesis, and effects of novel phenylpyrimidines as glucagon receptor antagonists.
Choi H; Lee CY; Park EY; Lee KM; Shin D; Jun HS
Bioorg Med Chem; 2018 Nov; 26(21):5701-5710. PubMed ID: 30366787
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anti-diabetic activity of novel biphenylsulfonamides as glucagon receptor antagonists.
Lee CY; Choi H; Park EY; Nguyen TT; Maeng HJ; Mee Lee K; Jun HS; Shin D
Chem Biol Drug Des; 2021 Nov; 98(5):733-750. PubMed ID: 34310065
[TBL] [Abstract][Full Text] [Related]
3. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
4. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
Irwin N; Franklin ZJ; O'Harte FP
Eur J Pharmacol; 2013 Jun; 709(1-3):43-51. PubMed ID: 23562625
[TBL] [Abstract][Full Text] [Related]
5. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
6. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.
Liang R; Abrardo L; Brady EJ; Candelore MR; Ding V; Saperstein R; Tota LM; Wright M; Mock S; Tamvakopolous C; Tong S; Zheng S; Zhang BB; Tata JR; Parmee ER
Bioorg Med Chem Lett; 2007 Feb; 17(3):587-92. PubMed ID: 17126016
[TBL] [Abstract][Full Text] [Related]
8. Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.
Yang X; Yates ML; Candelore MR; Feeney W; Hora D; Kim RM; Parmee ER; Berger JP; Zhang BB; Qureshi SA
Eur J Pharmacol; 2007 Jan; 555(1):8-16. PubMed ID: 17140563
[TBL] [Abstract][Full Text] [Related]
9. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.
Liang Y; Osborne MC; Monia BP; Bhanot S; Gaarde WA; Reed C; She P; Jetton TL; Demarest KT
Diabetes; 2004 Feb; 53(2):410-7. PubMed ID: 14747292
[TBL] [Abstract][Full Text] [Related]
10. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
11. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
13. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
[TBL] [Abstract][Full Text] [Related]
14. New beta-alanine derivatives are orally available glucagon receptor antagonists.
Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
Xu G; Gaul MD; Song F; Du F; Liang Y; DesJarlais RL; DiLoreto K; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
Bioorg Med Chem Lett; 2019 Oct; 29(20):126668. PubMed ID: 31519374
[TBL] [Abstract][Full Text] [Related]
17. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
Mani BK; Uchida A; Lee Y; Osborne-Lawrence S; Charron MJ; Unger RH; Berglund ED; Zigman JM
Diabetes; 2017 Jul; 66(7):1847-1857. PubMed ID: 28487437
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes.
Neumann UH; Ho JSS; Chen S; Tam YYC; Cullis PR; Kieffer TJ
Mol Metab; 2017 Oct; 6(10):1161-1172. PubMed ID: 29031717
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists.
O'Harte FP; Franklin ZJ; Rafferty EP; Irwin N
Mol Cell Endocrinol; 2013 Dec; 381(1-2):26-34. PubMed ID: 23891841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
